Your browser doesn't support javascript.
loading
Safety of endovascular treatment beyond the 6-h time window in 205 patients.
Jung, S; Gralla, J; Fischer, U; Mono, M-L; Weck, A; Lüdi, R; Heldner, M R; Findling, O; El-Koussy, M; Brekenfeld, C; Schroth, G; Mattle, H P; Arnold, M.
Afiliação
  • Jung S; Department of Neurology, Inselspital, University Hospital Bern and University of Berne, Berne, Switzerland.
Eur J Neurol ; 20(6): 865-71, 2013 Jun.
Article em En | MEDLINE | ID: mdl-23293861
ABSTRACT
BACKGROUND AND

PURPOSE:

Intra-arterial treatment (IAT) is effective when performed within 6 h of symptom onset in selected stroke patients ('T < 6H'). Its safety and efficacy is unclear when the patient has had symptoms for more than 6 h ('T > 6H') or for an unknown time (unclear-onset stroke, UOS), or woke up with a stroke (wake-up stroke, WUS). In this study we compared the safety of IAT in these four patient groups.

METHODS:

Eight-hundred and fifty-nine patients treated with IAT were enrolled. The main outcome parameters were clinical outcome [excellent modified Rankin Scale (mRS) 0 or 1; or favorable mRS 0-2] or mortality 3 months after treatment. Further outcome parameters were the rates of vessel recanalization, and cerebral and systemic hemorrhage.

RESULTS:

Six-hundred and fifty-four patients were treated before (T < 6H) and 205 after 6 h or an unknown time (128 T > 6H, 55 WUS and 22 UOS). NIHSS scores were higher in UOS patients than in T < 6H patients, vertebrobasilar occlusion was more common in T > 6H and UOS patients, and middle cerebral artery occlusions less common in T > 6H than in T < 6H patients. Other baseline characteristics were similar. There was no significant difference in clinical outcome and the rate of hemorrhage in multivariable regression analysis.

CONCLUSIONS:

Clinical outcome of our four groups of patients was similar with no increase of hemorrhage rates in patients treated after awakening, after an unknown time or more than 6 h. Our preliminary data suggest that treatment of such patients may be performed safely. If confirmed in randomized trials, this would have major clinical implications.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativador de Plasminogênio Tipo Uroquinase / Terapia Trombolítica / Acidente Vascular Cerebral / Procedimentos Endovasculares Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativador de Plasminogênio Tipo Uroquinase / Terapia Trombolítica / Acidente Vascular Cerebral / Procedimentos Endovasculares Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Suíça